Albumin has a long serum half-life due to its unique ability to bind the cellular neonatal Fc receptor (FcRn), which provides protection from intracellular degradation. The interaction can be capitalized to improve the efficacy of drugs by extending their serum persistence. However, species-specific binding of albumin to FcRn challenges preclinical development. The goal of this brief review is to provide insights into how FcRn and cross-species binding differences affect the pharmacokinetics of human serum albumin (HSA) in different animal models, and gives an overview of genetically modified mice that may serve as improved models for testing of albumin-based drugs.

白蛋白具有独特的结合细胞新生Fc受体（FcRn）的能力，因而具有较长的血清半衰期，从而可以防止细胞内降解。通过延长其血清持久性，可以利用这种相互作用来提高药物的疗效。但是，白蛋白与FcRn的物种特异性结合挑战了临床前开发。这篇简短综述的目的是提供有关FcRn和跨物种结合差异如何影响不同动物模型中人血清白蛋白（HSA）药代动力学的见解，并概述可作为改良测试模型的转基因小鼠白蛋白类药物。